Shares of Biogen Inc. BIIB shed 1.16% to $141.43 Wednesday, on what proved to be an all-around great trading session for the ...

Bullish option flow detected in Biogen (BIIB) with 2,540 calls trading, 1.1x expected, and implied vol increasing over 2 points to 35.32%.

Biogen Canada Inc. is pleased to announce that Health Canada has approved SKYCLARYS™ (omaveloxolone) for the treatment of Friedreich's ataxia (FA) in patients 16 years of age and older.2 This approval ...

BREYANZI has significant market potential due to its innovative approach as a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. The growing prevalence of hematologic malignancies ...

DelveInsight's 'BREYANZI Market Size, Forecast, and Market Insight Report' highlights the details around BREYANZI, a CD19-directed CAR ...

The stock's fall snapped a seven-day winning streak.

Global Phase 3 TRANSCEND study will evaluate the efficacy and safety of felzartamab, as compared to placebo, in adults with late AMRAMR is a ...

When it comes to recipes, I have a few nonnegotiables: simple, healthy and delicious! These creations are terrific for when you’re craving a quick breakfast or scrumptious afternoon snack: my ...

The global gene therapy market is projected to grow from $8.85 billion in 2024 to $36.55 billion by 2032, at a CAGR of 19.4%. This growth is driven by increasing R&D investments, approvals of novel ...

An icon of 3 horizontal dots. An icon of a paper envelope. An icon of a facebook f logo. An icon of a digital camera. An icon of a house. An icon of the Instagram logo. An icon of the LinkedIn logo.

Kylie Bromley, general manager for Biogen, one of lecanemab’s manufacturers, said, “We are encouraged that the dialogue to secure reimbursement for lecanemab will continue. Together with Eisai we look ...

The increasing occurrence of chronic and infectious diseases is the main driver of the rising demand for interferon. Furthermore, advancements in interferon production and ongoing research and ...